Lv1
20 积分 2024-11-17 加入
Real-World Outcomes with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective Study
3小时前
待确认
Phase Ib study with expansion of ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory CNS lymphoma
4小时前
已完结
Comparative safety of different first-line treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic review and network meta-analysis
9个月前
已完结
RCHOP plus BTK Inhibitor Improves Clinical Outcomes in Double Expressor Diffuse Large B-Cell Lymphoma, Unlike RCHOP plus Lenalidomide
9个月前
已关闭
[Clinical Study of Ibrutinib Combined with Venetoclax Regimen in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma]
10个月前
已完结
Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases
10个月前
已完结
Pericardial events associated with ibrutinib‐based therapies for chronic lymphocytic leukaemia in two landmark trials
10个月前
已完结
皖公网安备34019202002308
